GlassScriptPhysician profile
Lydia D D'Souza
NPI 1932343746
$1,409.16
in general payments reported to CMS, 2019-2025
22 companies · $791 in 2025
The $791 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $14.81 · 2021: $72.97 · 2022: $78.06 · 2024: $335 · 2025: $791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,094 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,094.11 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $464.81 | 2024-2025 | Wegovy, Ozempic |
| Gilead Sciences, INC. | $160.69 | 2025 | Yeztugo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.36 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $104.75 | 2025 | |
| Dexcom, INC. | $92.80 | 2019-2024 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $68.46 | 2022-2025 | Aptima |
| Mannkind Corporation | $46.46 | 2019-2020 | |
| Medtronic, INC. | $40.43 | 2021-2022 | |
| Cranial Technologies, INC | $32.88 | 2021-2022 | |
| Dynavax Technologies Corporation | $29.45 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $27.62 | 2024 | Rexulti |
| Biowound Solutions, INC. | $26.39 | 2025 | Bio-Connekt |
| Amgen INC. | $25.00 | 2024 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.60 | 2024 | Xifaxan |
| Abbott Laboratories | $24.50 | 2024 | Freestyle Libre 3 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $22.80 | 2024 | Zepbound, Mounjaro |
| Sanofi-Aventis U.S. LLC | $19.36 | 2025 | |
| Zimmer Biomet Holdings, INC. | $17.86 | 2024 | Gel-One Cross-Linked Hyaluronate |
| Insulet Corporation | $16.84 | 2021 | |
| Daiichi Sankyo INC. | $16.07 | 2021 | |
| Coopersurgical, INC. | $13.70 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lydia D'Souza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.